Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Igc Pharma Inc (IGC)

Igc Pharma Inc (IGC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,256
  • Shares Outstanding, K 77,449
  • Annual Sales, $ 1,350 K
  • Annual Income, $ -13,000 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta 1.32
  • Price/Sales 19.32
  • Price/Cash Flow N/A
  • Price/Book 3.44
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.18
  • Most Recent Earnings $-0.02 on 11/12/24
  • Next Earnings Date 02/12/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 445.91% ( +15.30%)
  • Historical Volatility 57.90%
  • IV Percentile 38%
  • IV Rank 24.54%
  • IV High 1,307.26% on 01/17/24
  • IV Low 165.85% on 10/21/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 30
  • Volume Avg (30-Day) 30
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 2,612
  • Open Int (30-Day) 2,398

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.03
  • Number of Estimates 1
  • High Estimate -0.03
  • Low Estimate -0.03
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3110 +6.11%
on 01/14/25
0.4082 -19.16%
on 12/16/24
-0.0839 (-20.27%)
since 12/13/24
3-Month
0.3110 +6.11%
on 01/14/25
0.4300 -23.26%
on 10/22/24
-0.0450 (-12.00%)
since 10/15/24
52-Week
0.2651 +24.48%
on 01/24/24
0.9099 -63.73%
on 04/04/24
+0.0644 (+24.25%)
since 01/12/24

Most Recent Stories

More News
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fireside...

IGC : 0.3281 (+0.61%)
IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

Innovative use of geofencing technology boosts enrollment at select sites

IGC : 0.3281 (+0.61%)
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

POTOMAC, MD / ACCESSWIRE / December 19, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced that the Company's management team will participate in BIO Partnering @ JPM,...

IGC : 0.3281 (+0.61%)
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

New trials to evaluate IGC-AD1's potential impact on amyloid plaque, tau tangles, and cognitive decline in Alzheimer's disease

IGC : 0.3281 (+0.61%)
IGC Pharma (NYSE American: IGC) Announces Results of Annual Meeting

IGC Pharma (NYSE American: IGC) has announced that during its annual meeting of stockholders scheduled for and convened on Aug. 18, 2023, (the “annual meeting”), all proposals as disclosed on the Definitive...

IGC : 0.3281 (+0.61%)
IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2024 Financial Report

IGC Pharma (NYSE American: IGC), a company that develops advanced cannabinoid-based formulations for treating diseases and conditions, including but not limited to Alzheimer’s disease, period cramps...

IGC : 0.3281 (+0.61%)
IGC Pharma (NYSE American: IGC) Announces Participation in Planet MicroCap Showcase

IGC Pharma (NYSE American: IGC) will be presenting at this month’s Planet MicroCap Showcase: VEGAS 2023; the event is slated for Wednesday, April 26, 2023, at 7:30 p.m. ET. According to the announcement,...

IGC : 0.3281 (+0.61%)
IGC Pharma to Attend Investor Summit

Potomac, Maryland--(Newsfile Corp. - March 22, 2023) - IGC Pharma, Inc. (NYSE American: IGC) ("IGC" or the "Company") today announced that Ram Mukunda, Chief Executive Officer, and Claudia Grimaldi, Principle...

IGC : 0.3281 (+0.61%)
India Globalization Capital (NYSE American: IGC) Fighting Alzheimer’s with Treatments in Study Phase

Key legislation designed to fight Alzheimer’s has been introduced in Congress — or actually reintroduced: the NAPA Reauthorization Act was first introduced in the last Congress but is seeing continued...

IGC : 0.3281 (+0.61%)
India Globalization Capital (NYSE American: IGC) Leads the Way with Cannabis-Based Treatment for Alzheimer’s

In groundbreaking work that establishes its commitment to being a pioneer in the treatment of Alzheimer’s disease, India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational...

IGC : 0.3281 (+0.61%)

Business Summary

IGC Pharma Inc. develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. IGC Pharma Inc., formerly known as India Globalization Capital Inc., is based in POTOMAC, Md....

See More

Key Turning Points

3rd Resistance Point 0.3969
2nd Resistance Point 0.3767
1st Resistance Point 0.3514
Last Price 0.3281
1st Support Level 0.3059
2nd Support Level 0.2857
3rd Support Level 0.2604

See More

52-Week High 0.9099
Fibonacci 61.8% 0.6636
Fibonacci 50% 0.5875
Fibonacci 38.2% 0.5114
Last Price 0.3281
52-Week Low 0.2651

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar